{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-046468","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2023-12-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.418599+00:00","generated_at":"2026-06-07T05:45:23.604834+00:00","sec_items":["2.01","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Oragenics completes acquisition of Odyssey's concussion, NPC drug assets for $1M cash + 8M preferred shares","bullets":["Paid $1M cash and issued 8M Series F Preferred shares to Odyssey for assets including mTBI (concussion) and NPC drug candidates and nasal delivery device.","Joseph Michael Redmond appointed President with $396,000 base salary, eligible for 50% performance bonus, and 75,000 stock options at $5.40.","Kimberly Murphy remains CEO and board member; Redmond reports to her.","Series F Preferred is convertible into common stock; further details in prior 8-K from October 5, 2023.","Employment agreement has 1-year initial term with automatic renewal; severance includes 6-12 months base salary under certain conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-046468","json":"https://secwatch.observer/filing/0001493152-23-046468.json","markdown":"https://secwatch.observer/filing/0001493152-23-046468.md","text":"https://secwatch.observer/filing/0001493152-23-046468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315223046468/0001493152-23-046468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315223046468/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:45:23.604834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4468332393","claim":"Joseph Michael Redmond was appointed as President at ORAGENICS INC.","evidence_excerpt":"the Company entered into an Executive Employment Agreement with Joseph Michael Redmond, pursuant to which he will serve as the President of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1174940/000149315223046468/0001493152-23-046468-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"fe59ab5d8e96706a0ae11c1da279eefa3d137072","claim":"ORAGENICS INC completed an acquisition involving Odyssey Health, Inc., f/k/a Odyssey Group International, Inc. for $1,000,000 in cash and issued 8,000,000 shares of convertible Series F Preferred Stock (closed 2023-12-28).","evidence_excerpt":"Pick Disease Type C (NPC), as well as Odyssey’s proprietary powder formulation and its nasal delivery device. In consideration for the Purchased Assets, the Company paid Odyssey $1,000,000 in cash and issued 8,000,000 shares of convertible Series F Preferred Stock to Odyssey. The Series F Preferred Stock is convertible into shares of the Company’s common stock, as","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1174940/000149315223046468/0001493152-23-046468-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Odyssey Health, Inc., f/k/a Odyssey Group International, Inc."},{"label":"Consideration","value":"$1,000,000 in cash and issued 8,000,000 shares of convertible Series F Preferred Stock"},{"label":"Closing","value":"2023-12-28"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}